Alzheimer’s disease research is increasingly focused on understanding what is happening inside the brain, not just observing symptoms. Tauklarify (florquinitau F 18) supports this effort by enabling the visualization of tau pathology through PET imaging.
Used in adults with cognitive impairment being evaluated for Alzheimer’s disease, Tauklarify helps identify tau neurofibrillary tangles, one of the key pathological features associated with the disease.
As diagnostic imaging becomes more important in Alzheimer’s research and treatment pathways, Tauklarify could become a relevant product to monitor for clinical studies involving neurodegenerative diseases.
